PROCEPT BioRobotics develops robotic surgical systems that treat benign prostatic hyperplasia (BPH), commonly called an enlarged prostate. Its Aquablation technology offers a potentially compelling alternative to conventional prostate surgery, particularly because it aims to deliver durable symptom relief while preserving urinary continence and sexual function.

The attractive part of the business is not simply selling robots. It is building a large installed base of robotic systems that generate recurring revenue every time a hospital performs a procedure.

The investment opportunity comes from the growing divergence between clinical adoption and investor confidence. PRCT's share price has fallen dramatically, but procedure volumes continue to grow. The concern is that system sales, pricing and operating expenses are not yet translating that growth into improving profitability.

The central question is whether PROCEPT can turn its promising technology into a profitable, defensible medical-device franchise before competition, reimbursement pressure or cash consumption undermine shareholder returns.

My initial assessment is that PRCT offers potentially attractive upside at current prices, but deserves a substantially higher risk premium than an established, profitable surgical robotics company.

What the Market May Be Mispricing

First, PROCEPT's share price has been heavily repriced even as its clinical treatment opportunity and HYDROS rollout remain intact. Second, consumables may become the main economic driver rather than lumpy initial equipment purchases if system utilization matures. Third, if HYDROS changes mature-site productivity and commercial spending eventually scales, operating leverage could improve substantially.

The counterargument is equally important: the market may correctly be pricing a lasting utilization problem rather than a temporary execution setback.

BPH occurs when the prostate enlarges and obstructs urine flow, potentially causing frequent urination, interrupted sleep, a weak urinary stream and incomplete bladder emptying. Medicines help some patients, but others eventually need a procedure.

PROCEPT offers Aquablation, using real-time ultrasound imaging, robotic planning and a controlled waterjet to remove obstructive prostate tissue. Unlike conventional thermal ablation techniques, the tissue-removal portion of Aquablation does not rely on heat.

Its primary products are the legacy AquaBeam system and the newer HYDROS platform, which incorporates enhanced imaging, planning and workflow capabilities.

Segment / Brand / Business Unit	Role	Revenue / Growth	Economics / Position	Strategic Takeaway
Robotic systems (HYDROS and AquaBeam)	Hospitals purchase or lease capital equipment	~$29.1M U.S. system revenue in Q2 2026	Creates an installed base; revenue is lumpy	Placements are valuable to the extent they produce utilization
Single-use handpieces and other consumables	Disposable supplies for procedures	~$48.4M U.S. revenue in Q2 2026	Recurring, procedure-linked sales	Largest domestic revenue stream in Q2; long-term core economics
Service and accessories	Maintenance and related equipment	Included in related revenue categories	Supports customer relationships	Adds retention and service economics
International	Systems, disposables and services outside the U.S.	Growing opportunity; smaller current business	Geographic expansion	Long-duration runway

PROCEPT sells into hospitals, while urologists influence usage and patient selection. It spends on clinical studies, surgical education, sales teams and commercial programs to expand the installed base and procedure volumes.

Business Takeaway

The most valuable part of the franchise is the recurring revenue opportunity. Installed systems create a customer relationship; procedure volume determines how much that relationship ultimately earns. A robot performing 100 procedures annually has a very different economic value from one performing 30.

PROCEPT targets a substantial established market rather than creating an entirely new category. BPH is common among aging men, and surgical treatment is already reimbursed and widely practiced.

The company estimated approximately 400,000 U.S. BPH procedures in 2024. It performed roughly 43,300 U.S. Aquablation procedures in 2025, implying penetration in the neighborhood of 11% when compared with that prior-year market estimate. Because periods and market definitions differ, this illustrates scale, not a precise audited market-share figure.

The opportunity is substantial even without assuming growth in patients seeking surgery. PROCEPT can gain share from TURP, laser enucleation, water-vapor therapy and other minimally invasive procedures.

Year	U.S. Aquablation procedures
2023	~16,500
2024	~27,800
2025	~43,300
2026E (company guidance midpoint)	~55,000

The 2026 midpoint implies about 27% growth over 2025, materially slower than the approximately 56% procedure growth in 2025.

Market-Share Analysis

A consistently defined, comparable market-share dataset for all BPH treatment competitors was not available. Competitors sell fundamentally different procedural technologies; equating placements or manufacturer revenue with procedure share would be misleading. The following competitive-position view is more useful.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
PROCEPT / Aquablation	Robotic tissue removal	Smaller installed base; fast expansion	Growth continues but slows in 2026	Upside depends on adoption and utilization
TURP and laser procedures	Established surgical standards	Deeply embedded in hospitals	Mature	Proven procedural alternatives
Boston Scientific / Rezūm	Water-vapor therapy	Diversified large device manufacturer	Established	Less invasive alternative
Teleflex / UroLift	Prostatic urethral lift	Established minimally invasive platform	Established	Competes for physician and patient selection
Olympus / iTind and instruments	Temporary implant and urology instruments	Extensive urology relationships	Established	Distribution and physician familiarity

Industry Takeaway

A large market and favorable clinical momentum support continued growth, but total market size is not realizable demand. Hospital budgets, surgeon preferences, patient selection, reimbursement and established alternatives constrain adoption.

Competitive Landscape

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Traditional TURP / HoLEP	Not comparable	Established surgical standards	Familiar, effective procedures; surgeon training and hospital equipment	Robotic waterjet may offer more standardized treatment and a favorable functional-outcome profile	Mature standard of care
Boston Scientific / Rezūm	Not disclosed comparably	Water-vapor minimally invasive therapy	Less invasive approach and large sales organization	Tissue removal may offer different efficacy/durability for selected patients	Established alternative
Teleflex / UroLift	Not disclosed comparably	Prostatic urethral lift	Less invasive, often office-oriented workflow	Aquablation may address more substantial obstruction	Established alternative
Olympus / iTind and instruments	Not disclosed comparably	Temporary implant and urologic tools	Urology relationships, scale and infrastructure	Integrated robotic waterjet platform is differentiated	Established alternative

Clinical support is meaningful. A May 2026 AUA guideline update strengthened Aquablation's recommendation for prostates of 30–80 mL and recognized its potential use for 80–150 mL prostates. WATER III clinical findings support attractive functional outcomes against laser treatment, although short follow-up and study-design limits constrain generalization.

Moat Assessment

The main moat sources are proprietary technology, clinical evidence, regulatory authorization, physician training, distribution relationships and the growing installed base. Switching costs exist, but hospitals can support multiple BPH modalities and surgeons do not have to use Aquablation exclusively.

Moat direction: Strengthening, but not proven durable.

Competitive Takeaway

HYDROS and improved guidelines reinforce PROCEPT's clinical differentiation, while weaker legacy utilization challenges confidence in long-term customer retention and procedure intensity.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2023	$136.2	81.6%	52.2%	−80.2%	−$133.2	−97.8%	$19.1	47.3	$257.2	~$52.0
FY2024	$224.5	64.8%	61.1%	−43.0%	−$103.6	−46.2%	$31.8	52.1	$333.7	$51.5
FY2025	$308.1	37.2%	63.7%	−33.7%	−$58.3	−18.9%	$47.6	55.5	$286.5	$51.6
Q1 FY2026	$83.132	N/D	64.9%	-39.2%	−$41.041 (derived: CFO - capex)	-49.4%	$13.072	56.511	$245.641	N/D
Q2 FY2026	$94.498	N/D	66.0%	-29.0%	−$22.204 (derived: current YTD - prior YTD)	-23.5%	$14.534 (derived: current YTD - prior YTD)	57.067	$227.914	N/D
H1 FY2026	$177.631	N/D	65.5%	-33.8%	−$63.245 (derived: CFO - capex)	-35.6%	$27.606	56.79	$227.914	N/D
Q3 FY2026	$98.291	N/D	66.3%	-27.9%	−$9.652 (derived: current YTD - prior YTD)	-9.8%	$15.08 (derived: current YTD - prior YTD)	57.326	$218.369	N/D
9M FY2026	$275.922	N/D	65.8%	-31.7%	−$72.897 (derived: CFO - capex)	-26.4%	$42.686	56.971	$218.369	N/D

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Diluted shares equal basic weighted-average shares during loss periods.

Financial Takeaways

Revenue growth is slowing considerably. Growth fell from 65% in 2024 to 37% in 2025 and approximately 20% in H1 2026. Full-year guidance of $390M–$410M implies second-half acceleration, which is not guaranteed.

Gross margins are improving over the long term, but Q2 quality was weaker than the headline suggests. Q2 2026 reported gross margin around 66% included a $2.9M one-time tariff refund. Without that refund, implied margin was roughly 63%, below the reported figure and prior-year level.

Operating leverage has stalled. First-half operating margin near negative 34% resembles FY2025. Revenue growth is not yet sufficiently exceeding commercial and development spending.

Cash burn is the most significant financial concern. H1 FCF deteriorated to −$63.2M from −$36.7M in H1 2025. Accounts receivable and inventory grew, contributing to working-capital consumption.

SBC is material. It equaled approximately 15.5% of revenue in both FY2025 and H1 2026. Excluding it from adjusted EBITDA does not remove the impact of potential dilution.

At June 30, PROCEPT held $227.9M unrestricted cash and roughly $51.7M long-term debt. In September 2026, loan maturity was extended from October 2027 to October 2028. This improves flexibility, but sustained cash consumption would reduce the buffer.

Financial direction: Mixed, leaning negative. Gross-margin progress and revenue scale are positives; dependable cash generation remains unproven.

Current Valuation

Metric	Value
Price Snapshot	$20.17 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	~$1.05B
Enterprise Value	~$0.90B, including lease adjustments
Trailing Revenue	~$337M
EV / Trailing Revenue	~2.7×
EV / 2026 Guided Revenue	~2.2× (at $400M midpoint)
P/E	Not meaningful — losses
FCF Multiple	Not meaningful — negative FCF
Shares Outstanding	~57.3M
June 2026 Net Cash, Excluding Leases	~$176M

Only the price row is refreshed here. Other quoted valuation statistics retain their earlier source dates and definitions.

Comparable Company Analysis

Company	Relevance	Public / Private	EV / Sales	P/E	Growth / Margin / Risk Context
PROCEPT BioRobotics	Subject company	Public	~2.7×	N/M	High growth; negative operating income and FCF
Boston Scientific	Rezūm direct operating competitor; diversified valuation anchor	Public	~3.7×	N/A — not used for comparison	Scaled profitable diversified medical device business
Teleflex	UroLift direct operating competitor; diversified valuation anchor	Public	~3.6×	N/A — not used for comparison	Established business with lower growth
Olympus	Urologic equipment competitor; secondary valuation anchor	Public	~1.9×	N/A — not used for comparison	Much larger, profitable, slower-growing diversified business

Comparable takeaway: The peer comparison offers perspective, not a direct valuation formula. PROCEPT's discount to some diversified device manufacturers looks attractive, but those companies generate profits and have more diversified revenue streams. PRCT could earn a premium if HYDROS becomes a dependable, profitable growth platform; conversely, its multiple could fall further if procedures weaken while losses persist.

Valuation Scenarios

The primary method is a 2028 enterprise-value-to-revenue model, discounted to the snapshot at 13% annually over two years. Each scenario incorporates estimated 2028 revenue, exit EV/sales, net cash and diluted shares. These are analyst assumptions, not company guidance.

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	2028 revenue $450M; EV/sales 1.7×; net cash $30M; 66M diluted shares	$9.43	30%	Persistent utilization issues, inefficient spending or dilutive funding remain credible	-53.2%
Base	2028 revenue $600M; EV/sales 3.25×; net cash $115M; 63M diluted shares	$25.67	50%	Continued slower growth plus improving operating economics is plausible	+27.3%
Bull	2028 revenue $760M; EV/sales 4.6×; net cash $150M; 61.5M diluted shares	$46.43	20%	Strong HYDROS adoption and procedure momentum are possible but unproven	+130.2%
Probability-Weighted	Present value of scenario outcomes	$24.95	100%	30% bear, 50% base, 20% bull	+23.7%

Bear-case probability is substantial because utilization, commercial efficiency and cash conversion remain uncertain. Returns compare the present fair values with the October 19 price; they are not annualized forecasts.

Valuation Takeaway

• Primary valuation method: 2028 EV/revenue scenario model discounted at 13% annually.
• Cross-check methods: Current EV/trailing sales, EV/guided 2026 sales and diversified medical-device peer EV/sales.
• Key valuation dependencies: Procedure utilization, 2028 revenue, sustainable margins, cash burn, net cash, exit multiple and fully diluted shares.
• Valuation confidence / Risk Level: High risk / low-to-moderate confidence; scenario outcomes are exceptionally wide.
• Margin-of-safety conclusion: Probability-weighted fair value ~$24.95 implies about 36.5% upside from $18.28, but the bear case loses 48.4%; this is a speculative Buy, not a high-confidence bargain.

Derived zones under the current methodology: Strong Buy ≤ $10.38; Buy >$10.38 through $19.96; Hold / Watch >$19.96 through $27.72; Avoid >$27.72.

CEO Larry Wood has helped commercialize HYDROS and expand clinical adoption. Management is investing in physician training, commercial reorganization, consumer awareness and clinical indications.

The 2026 procedure-guidance reduction from 60,000–64,000 to 54,000–56,000 is significant. Management also increased expected adjusted EBITDA losses while acknowledging incomplete understanding of the legacy AquaBeam utilization decline.

The central allocation question is whether commercial spending creates enough incremental procedures. Building a larger sales force without improving same-site demand would be poor capital productivity.

Securities class-action litigation filed in July 2026 adds governance and disclosure risk. Allegations concerning handpiece sales, procedures, discounting and guidance remain unproven; no adverse finding should be presumed. The allegations overlap with key operating metrics investors should scrutinize.

Management Takeaway

Management has demonstrated product and placement execution. Guidance reliability and sales-spending efficiency must improve before higher confidence in its capital allocation is warranted.

Analyzed call: Q2 2026 earnings call, 2026-08-04 · Research snapshot: 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-20)

The complete material August 4, 2026 earnings-call Q&A was reviewed in the research presented in chat; related follow-ups are consolidated.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Matthew O'Brien / Piper Sandler	How do system placements, replacements and recurring sales support 2026 revenue?	Management outlined expected system revenue, handpiece revenue and international contribution.	Capital sales offset some procedure weakness; mix needs monitoring.
Brandon Vazquez / William Blair	Why are older AquaBeam sites underperforming, and will the sales realignment fix them?	Management acknowledged incomplete understanding of the utilization decline, emphasizing stronger HYDROS performance.	Most important unresolved question.
Nathan Treybeck / Wells Fargo	Could reimbursement changes or alternative treatments hurt demand?	Management defended the clinical and economic positioning.	Reimbursement and competitive sensitivity remain material.
Vijay Kumar / Evercore	Why are systems selling when utilization is weaker? Are 2027 targets intact?	Management emphasized ASP strength; described earlier 2027 revenue expectations as broadly plausible but deferred formal guidance.	Revenue confidence exceeds utilization and margin visibility.
Stephanie Elghazi / BofA	What drove the ~7,000 reduction in procedure guidance? Why more spending?	Lower-end guidance assumes no material legacy-utilization recovery; investment includes direct-to-consumer programs in 18 markets.	Continuing weakness is partly reflected in guidance, but demand-generation ROI is unproven.
Richard Newitter / Truist	Can H2 acceleration and future operating leverage be delivered?	Management cited launch-team expansion, seasonality and expected profitability improvement.	Execution remains back-half weighted.
Stephens analyst	Do targets require big health-system orders or pulled-forward purchases?	Management said unusually large multi-system deals were not assumed.	Some reassurance on placement-guidance quality.
David Rescott / Baird	How do replacements affect pricing and margins?	Management discussed lower replacement ASPs and future recurring procedure revenue.	Upgrades can improve later utilization but affect near-term sales mix.
Mike Kratky / Leerink	Can management quantify the utilization uplift from new launch teams?	Management described encouraging outcomes but did not quantify an uplift.	Productivity improvement cannot yet be underwritten precisely.
Suraj Kalia / Oppenheimer	Why stress total procedure growth over per-system utilization?	Management emphasized sequential gains and stronger HYDROS accounts.	Aggregate growth can conceal mature-site weakness.
Josh Jennings / TD Cowen	Is consumer advertising generating measurable demand?	Management said patient-scheduling delays made quantification premature.	Advertising ROI is unproven.
Ryan Zimmerman / BTIG	Are H2 placements realistic and is demand being pulled forward?	Management reaffirmed ~210–220 new U.S. systems expected in 2026.	Requires a meaningful second-half placement ramp.

Analyst-Q&A Takeaway

Three unanswered questions stand out: why older systems are underused, whether commercial spending creates incremental procedures, and whether profitability expectations withstand lower utilization. Management did not dismiss the issue, but has not demonstrated a durable solution or provided metrics granular enough to independently verify one.

Source	Type	Date / Period	What It Supports
2025 Form 10-K	Regulatory filing	FY2023–FY2025	Company business, historical financials, industry size, risks
Q2 2026 Form 10-Q	Regulatory filing	H1 2026	Cash flow, balance sheet, operating trends, SBC
Q2 2026 earnings release	Company IR	2026-08-04	System sales, procedures, revenue and guidance
Q2 2026 earnings-call transcript	Transcript	2026-08-04	Management commentary, utilization, all material analyst Q&A
AUA guideline update	Company IR / clinical guidelines	2026-05-14	Clinical positioning and applicable prostate sizes
WATER III research	Clinical research	2026	Comparative surgical evidence
Debt extension Form 8-K	Regulatory filing	2026-09-23	Loan maturity and liquidity
PRCT market price history	Market data	2026-10-19	Valuation price snapshot and market capitalization
Boston Scientific valuation data	Market / comparable data	October 2026	Secondary valuation anchor
Teleflex valuation data	Market / comparable data	October 2026	Direct operating competitor and valuation anchor
Olympus investor relations	Competitor company data	2026	Operating competitor and diversified valuation anchor
PRCT common regular-close snapshot	Market data	2026-10-20 16:00 EDT	Refreshed price, scenario returns and normalized Opportunity Score / shared rank
SEC XBRL company facts — PRCT	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: PROCEPT BioRobotics Corporation

• Ticker: PRCT

• Exchange: NASDAQ

• Sector / Industry: Health Care / Medical Devices and Surgical Robotics (Urology)

• Template version: 2.7

• Research date: 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-20)

• Valuation / score price snapshot: $20.17 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026 and H1 2026

• Historical period reviewed: FY2023–FY2025 plus H1 2026

• Latest investor presentation reviewed: Q2 2026 earnings materials, 2026-08-04; no separate investor presentation reviewed

• Latest earnings call reviewed: Q2 2026 earnings call, 2026-08-04

• Latest post-earnings management commentary reviewed: September 2026 debt amendment filing; no additional management conference transcript reviewed

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

PROCEPT BioRobotics Corporation (PRCT) — Investment Analysis

Company & Research Metadata

• Company: PROCEPT BioRobotics Corporation

• Ticker: PRCT

• Exchange: NASDAQ

• Sector / Industry: Health Care / Medical Devices and Surgical Robotics (Urology)

• Template version: 2.7

• Research date: 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-20)

• Valuation / score price snapshot: $20.17 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026 and H1 2026

• Historical period reviewed: FY2023–FY2025 plus H1 2026

• Latest investor presentation reviewed: Q2 2026 earnings materials, 2026-08-04; no separate investor presentation reviewed

• Latest earnings call reviewed: Q2 2026 earnings call, 2026-08-04

• Latest post-earnings management commentary reviewed: September 2026 debt amendment filing; no additional management conference transcript reviewed

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-20)

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Company-specific rivals reviewed; relevant comparisons retained	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 12 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$20.17 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Hold / Watch
Bear / Base / Bull Fair Value	$9.43 / $25.67 / $46.43
Scenario Probabilities	30% / 50% / 20%
Probability-Weighted Fair Value	$24.95
Probability-Weighted Expected Return	+23.7%
Bear-Case Return	-53.2%
Strong Buy Zone	≤ $10.38
Buy Zone	>$10.38–$19.96
Avoid Chasing Above	> $27.72
Quality Score / Tier	61.9 / Tier C
Opportunity Score / Rank	58.7 / #28 of 76
Risk Level	High
Tracking / Ownership	Primary Watchlist / Not Owned

Decision rationale: PRCT offers potentially attractive upside at the analyzed price, but deserves a much higher risk premium than an established, profitable surgical robotics company. Its Aquablation technology and procedure-driven recurring revenue opportunity are compelling, yet weak utilization of older systems, declining free cash flow and persistent operating losses keep this a speculative rather than high-conviction Buy.

Investment Thesis

PROCEPT BioRobotics develops robotic surgical systems that treat benign prostatic hyperplasia (BPH), commonly called an enlarged prostate. Its Aquablation technology offers a potentially compelling alternative to conventional prostate surgery, particularly because it aims to deliver durable symptom relief while preserving urinary continence and sexual function.

The attractive part of the business is not simply selling robots. It is building a large installed base of robotic systems that generate recurring revenue every time a hospital performs a procedure.

The investment opportunity comes from the growing divergence between clinical adoption and investor confidence. PRCT's share price has fallen dramatically, but procedure volumes continue to grow. The concern is that system sales, pricing and operating expenses are not yet translating that growth into improving profitability.

The central question is whether PROCEPT can turn its promising technology into a profitable, defensible medical-device franchise before competition, reimbursement pressure or cash consumption undermine shareholder returns.

My initial assessment is that PRCT offers potentially attractive upside at current prices, but deserves a substantially higher risk premium than an established, profitable surgical robotics company.

What the Market May Be Mispricing

First, PROCEPT's share price has been heavily repriced even as its clinical treatment opportunity and HYDROS rollout remain intact. Second, consumables may become the main economic driver rather than lumpy initial equipment purchases if system utilization matures. Third, if HYDROS changes mature-site productivity and commercial spending eventually scales, operating leverage could improve substantially.

The counterargument is equally important: the market may correctly be pricing a lasting utilization problem rather than a temporary execution setback.

Business Overview

BPH occurs when the prostate enlarges and obstructs urine flow, potentially causing frequent urination, interrupted sleep, a weak urinary stream and incomplete bladder emptying. Medicines help some patients, but others eventually need a procedure.

PROCEPT offers Aquablation, using real-time ultrasound imaging, robotic planning and a controlled waterjet to remove obstructive prostate tissue. Unlike conventional thermal ablation techniques, the tissue-removal portion of Aquablation does not rely on heat.

Its primary products are the legacy AquaBeam system and the newer HYDROS platform, which incorporates enhanced imaging, planning and workflow capabilities.

Segment / Brand / Business Unit	Role	Revenue / Growth	Economics / Position	Strategic Takeaway
Robotic systems (HYDROS and AquaBeam)	Hospitals purchase or lease capital equipment	~$29.1M U.S. system revenue in Q2 2026	Creates an installed base; revenue is lumpy	Placements are valuable to the extent they produce utilization
Single-use handpieces and other consumables	Disposable supplies for procedures	~$48.4M U.S. revenue in Q2 2026	Recurring, procedure-linked sales	Largest domestic revenue stream in Q2; long-term core economics
Service and accessories	Maintenance and related equipment	Included in related revenue categories	Supports customer relationships	Adds retention and service economics
International	Systems, disposables and services outside the U.S.	Growing opportunity; smaller current business	Geographic expansion	Long-duration runway

PROCEPT sells into hospitals, while urologists influence usage and patient selection. It spends on clinical studies, surgical education, sales teams and commercial programs to expand the installed base and procedure volumes.

Business Takeaway

The most valuable part of the franchise is the recurring revenue opportunity. Installed systems create a customer relationship; procedure volume determines how much that relationship ultimately earns. A robot performing 100 procedures annually has a very different economic value from one performing 30.

Industry, TAM & Market Share

PROCEPT targets a substantial established market rather than creating an entirely new category. BPH is common among aging men, and surgical treatment is already reimbursed and widely practiced.

The company estimated approximately 400,000 U.S. BPH procedures in 2024. It performed roughly 43,300 U.S. Aquablation procedures in 2025, implying penetration in the neighborhood of 11% when compared with that prior-year market estimate. Because periods and market definitions differ, this illustrates scale, not a precise audited market-share figure.

The opportunity is substantial even without assuming growth in patients seeking surgery. PROCEPT can gain share from TURP, laser enucleation, water-vapor therapy and other minimally invasive procedures.

Year	U.S. Aquablation procedures
2023	~16,500
2024	~27,800
2025	~43,300
2026E (company guidance midpoint)	~55,000

The 2026 midpoint implies about 27% growth over 2025, materially slower than the approximately 56% procedure growth in 2025.

Market-Share Analysis

A consistently defined, comparable market-share dataset for all BPH treatment competitors was not available. Competitors sell fundamentally different procedural technologies; equating placements or manufacturer revenue with procedure share would be misleading. The following competitive-position view is more useful.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
PROCEPT / Aquablation	Robotic tissue removal	Smaller installed base; fast expansion	Growth continues but slows in 2026	Upside depends on adoption and utilization
TURP and laser procedures	Established surgical standards	Deeply embedded in hospitals	Mature	Proven procedural alternatives
Boston Scientific / Rezūm	Water-vapor therapy	Diversified large device manufacturer	Established	Less invasive alternative
Teleflex / UroLift	Prostatic urethral lift	Established minimally invasive platform	Established	Competes for physician and patient selection
Olympus / iTind and instruments	Temporary implant and urology instruments	Extensive urology relationships	Established	Distribution and physician familiarity

Industry Takeaway

A large market and favorable clinical momentum support continued growth, but total market size is not realizable demand. Hospital budgets, surgeon preferences, patient selection, reimbursement and established alternatives constrain adoption.

Customer Economics

In Q2 2026, new HYDROS systems sold for approximately $495,000 on average, while single-use handpieces averaged $3,550. At that handpiece price, 100 procedures generate about $355,000 in annual gross handpiece sales before discounts, product costs and other expenses. This illustrates why utilization can ultimately matter more than the initial capital sale.

The company delivered 65 U.S. HYDROS systems in Q2 2026: 50 new installations, 14 replacements and one lease. Replacements strengthen the installed base technologically but do not add customer sites.

The central concern is that older AquaBeam systems have experienced weaker procedure utilization, and management has not fully identified the cause. HYDROS systems are performing materially better, but the difference may reflect technology, physician enthusiasm, customer selection or installation age.

Customer-Economics Takeaway

The recurring revenue model is attractive only if systems maintain high and growing procedure volumes. The most useful operating measure is same-site procedure growth separated between mature AquaBeam and HYDROS sites, not total procedures divided by every installed robot.

Competitive Landscape & Moat

Competitive Landscape

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Traditional TURP / HoLEP	Not comparable	Established surgical standards	Familiar, effective procedures; surgeon training and hospital equipment	Robotic waterjet may offer more standardized treatment and a favorable functional-outcome profile	Mature standard of care
Boston Scientific / Rezūm	Not disclosed comparably	Water-vapor minimally invasive therapy	Less invasive approach and large sales organization	Tissue removal may offer different efficacy/durability for selected patients	Established alternative
Teleflex / UroLift	Not disclosed comparably	Prostatic urethral lift	Less invasive, often office-oriented workflow	Aquablation may address more substantial obstruction	Established alternative
Olympus / iTind and instruments	Not disclosed comparably	Temporary implant and urologic tools	Urology relationships, scale and infrastructure	Integrated robotic waterjet platform is differentiated	Established alternative

Clinical support is meaningful. A May 2026 AUA guideline update strengthened Aquablation's recommendation for prostates of 30–80 mL and recognized its potential use for 80–150 mL prostates. WATER III clinical findings support attractive functional outcomes against laser treatment, although short follow-up and study-design limits constrain generalization.

Moat Assessment

The main moat sources are proprietary technology, clinical evidence, regulatory authorization, physician training, distribution relationships and the growing installed base. Switching costs exist, but hospitals can support multiple BPH modalities and surgeons do not have to use Aquablation exclusively.

Moat direction: Strengthening, but not proven durable.

Competitive Takeaway

HYDROS and improved guidelines reinforce PROCEPT's clinical differentiation, while weaker legacy utilization challenges confidence in long-term customer retention and procedure intensity.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2023	$136.2	81.6%	52.2%	−80.2%	−$133.2	−97.8%	$19.1	47.3	$257.2	~$52.0
FY2024	$224.5	64.8%	61.1%	−43.0%	−$103.6	−46.2%	$31.8	52.1	$333.7	$51.5
FY2025	$308.1	37.2%	63.7%	−33.7%	−$58.3	−18.9%	$47.6	55.5	$286.5	$51.6
Q1 FY2026	$83.132	N/D	64.9%	-39.2%	−$41.041 (derived: CFO - capex)	-49.4%	$13.072	56.511	$245.641	N/D
Q2 FY2026	$94.498	N/D	66.0%	-29.0%	−$22.204 (derived: current YTD - prior YTD)	-23.5%	$14.534 (derived: current YTD - prior YTD)	57.067	$227.914	N/D
H1 FY2026	$177.631	N/D	65.5%	-33.8%	−$63.245 (derived: CFO - capex)	-35.6%	$27.606	56.79	$227.914	N/D
Q3 FY2026	$98.291	N/D	66.3%	-27.9%	−$9.652 (derived: current YTD - prior YTD)	-9.8%	$15.08 (derived: current YTD - prior YTD)	57.326	$218.369	N/D
9M FY2026	$275.922	N/D	65.8%	-31.7%	−$72.897 (derived: CFO - capex)	-26.4%	$42.686	56.971	$218.369	N/D

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Supplemental historical reporting context (retained)

Diluted shares equal basic weighted-average shares during loss periods.

Financial Takeaways

Revenue growth is slowing considerably. Growth fell from 65% in 2024 to 37% in 2025 and approximately 20% in H1 2026. Full-year guidance of $390M–$410M implies second-half acceleration, which is not guaranteed.

Gross margins are improving over the long term, but Q2 quality was weaker than the headline suggests. Q2 2026 reported gross margin around 66% included a $2.9M one-time tariff refund. Without that refund, implied margin was roughly 63%, below the reported figure and prior-year level.

Operating leverage has stalled. First-half operating margin near negative 34% resembles FY2025. Revenue growth is not yet sufficiently exceeding commercial and development spending.

Cash burn is the most significant financial concern. H1 FCF deteriorated to −$63.2M from −$36.7M in H1 2025. Accounts receivable and inventory grew, contributing to working-capital consumption.

SBC is material. It equaled approximately 15.5% of revenue in both FY2025 and H1 2026. Excluding it from adjusted EBITDA does not remove the impact of potential dilution.

At June 30, PROCEPT held $227.9M unrestricted cash and roughly $51.7M long-term debt. In September 2026, loan maturity was extended from October 2027 to October 2028. This improves flexibility, but sustained cash consumption would reduce the buffer.

Financial direction: Mixed, leaning negative. Gross-margin progress and revenue scale are positives; dependable cash generation remains unproven.

Management & Capital Allocation

CEO Larry Wood has helped commercialize HYDROS and expand clinical adoption. Management is investing in physician training, commercial reorganization, consumer awareness and clinical indications.

The 2026 procedure-guidance reduction from 60,000–64,000 to 54,000–56,000 is significant. Management also increased expected adjusted EBITDA losses while acknowledging incomplete understanding of the legacy AquaBeam utilization decline.

The central allocation question is whether commercial spending creates enough incremental procedures. Building a larger sales force without improving same-site demand would be poor capital productivity.

Securities class-action litigation filed in July 2026 adds governance and disclosure risk. Allegations concerning handpiece sales, procedures, discounting and guidance remain unproven; no adverse finding should be presumed. The allegations overlap with key operating metrics investors should scrutinize.

Management Takeaway

Management has demonstrated product and placement execution. Guidance reliability and sales-spending efficiency must improve before higher confidence in its capital allocation is warranted.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$20.17 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	~$1.05B
Enterprise Value	~$0.90B, including lease adjustments
Trailing Revenue	~$337M
EV / Trailing Revenue	~2.7×
EV / 2026 Guided Revenue	~2.2× (at $400M midpoint)
P/E	Not meaningful — losses
FCF Multiple	Not meaningful — negative FCF
Shares Outstanding	~57.3M
June 2026 Net Cash, Excluding Leases	~$176M

Only the price row is refreshed here. Other quoted valuation statistics retain their earlier source dates and definitions.

Comparable Company Analysis

Company	Relevance	Public / Private	EV / Sales	P/E	Growth / Margin / Risk Context
PROCEPT BioRobotics	Subject company	Public	~2.7×	N/M	High growth; negative operating income and FCF
Boston Scientific	Rezūm direct operating competitor; diversified valuation anchor	Public	~3.7×	N/A — not used for comparison	Scaled profitable diversified medical device business
Teleflex	UroLift direct operating competitor; diversified valuation anchor	Public	~3.6×	N/A — not used for comparison	Established business with lower growth
Olympus	Urologic equipment competitor; secondary valuation anchor	Public	~1.9×	N/A — not used for comparison	Much larger, profitable, slower-growing diversified business

Comparable takeaway: The peer comparison offers perspective, not a direct valuation formula. PROCEPT's discount to some diversified device manufacturers looks attractive, but those companies generate profits and have more diversified revenue streams. PRCT could earn a premium if HYDROS becomes a dependable, profitable growth platform; conversely, its multiple could fall further if procedures weaken while losses persist.

Valuation Scenarios

The primary method is a 2028 enterprise-value-to-revenue model, discounted to the snapshot at 13% annually over two years. Each scenario incorporates estimated 2028 revenue, exit EV/sales, net cash and diluted shares. These are analyst assumptions, not company guidance.

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	2028 revenue $450M; EV/sales 1.7×; net cash $30M; 66M diluted shares	$9.43	30%	Persistent utilization issues, inefficient spending or dilutive funding remain credible	-53.2%
Base	2028 revenue $600M; EV/sales 3.25×; net cash $115M; 63M diluted shares	$25.67	50%	Continued slower growth plus improving operating economics is plausible	+27.3%
Bull	2028 revenue $760M; EV/sales 4.6×; net cash $150M; 61.5M diluted shares	$46.43	20%	Strong HYDROS adoption and procedure momentum are possible but unproven	+130.2%
Probability-Weighted	Present value of scenario outcomes	$24.95	100%	30% bear, 50% base, 20% bull	+23.7%

Bear-case probability is substantial because utilization, commercial efficiency and cash conversion remain uncertain. Returns compare the present fair values with the October 19 price; they are not annualized forecasts.

Valuation Takeaway

• Primary valuation method: 2028 EV/revenue scenario model discounted at 13% annually.
• Cross-check methods: Current EV/trailing sales, EV/guided 2026 sales and diversified medical-device peer EV/sales.
• Key valuation dependencies: Procedure utilization, 2028 revenue, sustainable margins, cash burn, net cash, exit multiple and fully diluted shares.
• Valuation confidence / Risk Level: High risk / low-to-moderate confidence; scenario outcomes are exceptionally wide.
• Margin-of-safety conclusion: Probability-weighted fair value ~$24.95 implies about 36.5% upside from $18.28, but the bear case loses 48.4%; this is a speculative Buy, not a high-confidence bargain.

Derived zones under the current methodology: Strong Buy ≤ $10.38; Buy >$10.38 through $19.96; Hold / Watch >$19.96 through $27.72; Avoid >$27.72.

Analyst Questions

The complete material August 4, 2026 earnings-call Q&A was reviewed in the research presented in chat; related follow-ups are consolidated.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Matthew O'Brien / Piper Sandler	How do system placements, replacements and recurring sales support 2026 revenue?	Management outlined expected system revenue, handpiece revenue and international contribution.	Capital sales offset some procedure weakness; mix needs monitoring.
Brandon Vazquez / William Blair	Why are older AquaBeam sites underperforming, and will the sales realignment fix them?	Management acknowledged incomplete understanding of the utilization decline, emphasizing stronger HYDROS performance.	Most important unresolved question.
Nathan Treybeck / Wells Fargo	Could reimbursement changes or alternative treatments hurt demand?	Management defended the clinical and economic positioning.	Reimbursement and competitive sensitivity remain material.
Vijay Kumar / Evercore	Why are systems selling when utilization is weaker? Are 2027 targets intact?	Management emphasized ASP strength; described earlier 2027 revenue expectations as broadly plausible but deferred formal guidance.	Revenue confidence exceeds utilization and margin visibility.
Stephanie Elghazi / BofA	What drove the ~7,000 reduction in procedure guidance? Why more spending?	Lower-end guidance assumes no material legacy-utilization recovery; investment includes direct-to-consumer programs in 18 markets.	Continuing weakness is partly reflected in guidance, but demand-generation ROI is unproven.
Richard Newitter / Truist	Can H2 acceleration and future operating leverage be delivered?	Management cited launch-team expansion, seasonality and expected profitability improvement.	Execution remains back-half weighted.
Stephens analyst	Do targets require big health-system orders or pulled-forward purchases?	Management said unusually large multi-system deals were not assumed.	Some reassurance on placement-guidance quality.
David Rescott / Baird	How do replacements affect pricing and margins?	Management discussed lower replacement ASPs and future recurring procedure revenue.	Upgrades can improve later utilization but affect near-term sales mix.
Mike Kratky / Leerink	Can management quantify the utilization uplift from new launch teams?	Management described encouraging outcomes but did not quantify an uplift.	Productivity improvement cannot yet be underwritten precisely.
Suraj Kalia / Oppenheimer	Why stress total procedure growth over per-system utilization?	Management emphasized sequential gains and stronger HYDROS accounts.	Aggregate growth can conceal mature-site weakness.
Josh Jennings / TD Cowen	Is consumer advertising generating measurable demand?	Management said patient-scheduling delays made quantification premature.	Advertising ROI is unproven.
Ryan Zimmerman / BTIG	Are H2 placements realistic and is demand being pulled forward?	Management reaffirmed ~210–220 new U.S. systems expected in 2026.	Requires a meaningful second-half placement ramp.

Analyst-Q&A Takeaway

Three unanswered questions stand out: why older systems are underused, whether commercial spending creates incremental procedures, and whether profitability expectations withstand lower utilization. Management did not dismiss the issue, but has not demonstrated a durable solution or provided metrics granular enough to independently verify one.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
U.S. procedures	2026 guidance 54k–56k	Growth reaccelerates, guidance stabilizes	More cuts or sustained deceleration	Revenue forecasts and multiples
Mature-site utilization	AquaBeam weakness unresolved	Same-site volumes recover	Persistent deterioration	Moat and recurring revenue assumptions
HYDROS adoption	Strong placements and utilization	High usage sustained as sites age	Usage falls as installed sites mature	Growth durability
Gross margin	~65% full-year guidance	Sustainable gains excluding one-offs	Deteriorating margins on mix shift	Operating leverage
Cash flow	H1 FCF −$63M	Material reduction in burn and clear path to positive FCF	Continued cash drain or dilutive financing	Financial quality and fair value
Commercial efficiency	Higher spending; 18-market consumer pilot	Measurable patient activation and ROI	Rising customer-acquisition costs without utilization gains	Management score and margins
Clinical expansion	Better BPH guidelines; WATER IV investigational	Favorable evidence and approvals	Disappointing trials or delays	TAM and bull case
Governance / disclosure	Pending litigation	Clarity without adverse findings	Material adverse legal or reporting events	Confidence and valuation

Next checkpoint: Expected Q3 2026 results on November 4, 2026. Focus on procedure volumes, mature-site trends, guidance and cash consumption rather than just headline revenue.

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	62	25%	15.50	Attractive consumables model, weak current profitability
Moat and competitive position	67	25%	16.75	Differentiated technology, clinical evidence, meaningful competition
Growth runway and durability	80	20%	16.00	Large BPH opportunity and substantial penetration runway
Financial quality and balance sheet	43	15%	6.45	Cash runway but heavy burn and dilution
Management, governance and capital allocation	48	15%	7.20	Product execution offset by guidance cuts and utilization uncertainty
Quality Score	61.9	100%	61.90	Tier C

• Quality Tier: C
• Speculative override: None; commercial revenue and established clinical use exist. Investment remains high-risk.

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	61.9	61.9	30%	18.6
Probability-weighted upside	+23.7%	97.4	35%	34.1
Bear-case downside	-53.2%	0.0	20%	0.0
Risk / valuation confidence	40	40.0	15%	6.0
Opportunity Score		58.7	100%	58.7

• Opportunity Rank: #28 of 76
• Zone Status: Hold / Watch

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: No
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, share count, position size and cost basis do not alter Quality Score, Opportunity Score, rank, rating, valuation or valuation zones.

Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale | |---|---:|---|---|---|---|---|---:|---:|---:|---:|---:|---|---| | 2026-10-20 22:54 ET | $18.28 | Buy — Speculative | Buy | >$10.38–$19.96 | ≤$10.38 | >$27.72 | $25.67 | $24.95 | +36.5% | 61.9 / Tier C | 59.9 / Unassigned | Initial analysis; repricing creates upside but legacy utilization, cash burn and execution risks are substantial | | 2026-10-21 (America/New_York) | $18.82 | Buy — Speculative | Buy | >$10.38–$19.96 | ≤ $10.38 | > $27.72 | $25.67 | $24.95 | +32.6% | 61.9 | 59.6 / #25 | Common close and shared-universe rank; prior fundamental assumptions and zones preserved |

---

Material Sources

Source	Type	Date / Period	What It Supports
2025 Form 10-K	Regulatory filing	FY2023–FY2025	Company business, historical financials, industry size, risks
Q2 2026 Form 10-Q	Regulatory filing	H1 2026	Cash flow, balance sheet, operating trends, SBC
Q2 2026 earnings release	Company IR	2026-08-04	System sales, procedures, revenue and guidance
Q2 2026 earnings-call transcript	Transcript	2026-08-04	Management commentary, utilization, all material analyst Q&A
AUA guideline update	Company IR / clinical guidelines	2026-05-14	Clinical positioning and applicable prostate sizes
WATER III research	Clinical research	2026	Comparative surgical evidence
Debt extension Form 8-K	Regulatory filing	2026-09-23	Loan maturity and liquidity
PRCT market price history	Market data	2026-10-19	Valuation price snapshot and market capitalization
Boston Scientific valuation data	Market / comparable data	October 2026	Secondary valuation anchor
Teleflex valuation data	Market / comparable data	October 2026	Direct operating competitor and valuation anchor
Olympus investor relations	Competitor company data	2026	Operating competitor and diversified valuation anchor
PRCT common regular-close snapshot	Market data	2026-10-20 16:00 EDT	Refreshed price, scenario returns and normalized Opportunity Score / shared rank
SEC XBRL company facts — PRCT	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics